Clinical Trials in Acute CNS Injuries

  • F. Servadei
  • G. Giuliani
  • M. T. Nasi
  • A. Arista


Acute central nervous system injuries include head injury, spinal cord injury, focal and global cerebral ischemia and subarachnoid hemorrhage (SAH). Our paper focuses on brain injury and on SAH. Trauma is the first cause of death below the age of 45 in many countries all over the world (1); head injury contributes in the vast majority of cases. An average of 200 patients per 100.000 population per year are admitted to the hospital following a head injury. About 20 per 100.000 population per year are the deaths related to the brain injury (1). Many cases among the survivors present neurological sequelae leading to severe disability. SAH is less frequent (11 cases per 100.000 inhabitants per year); mortahty and morbidity in this disease are mainly related to the occurrence of vasospasm (40% to 60% of patients) (2). Both in brain injury and in SAH patients there is primary brain damage due to mechanical factors in head injuries and to hemorrhagic stroke in SAH. This primary damage is followed by secondary damage due to biochemical processes in the tissue surrounding the primary injury. Secondary ischemia, which is present both following brain injury and during vasospasm, leads to loss or reduction of blood flow and oxygen supply. With the improvement in our knowledge concerning this biochemically induced damage, a new set of drugs has been tested in animal models. A few of these drugs reached a phase II — III clinical trial both in SAH and in brain injured patients.


Severe Head Injury Aneurysmal Subarachnoid Hemorrhage Global Cerebral Ischemia Angiographic Vasospasm Oral Nimodipine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Kraus JF (1991) Epidemiologie features of injuries to the central nervous system. In: Anderson W, Schoenberg D (eds) Neuroepidemiology: a tribute to Bruce Schoenberg. CRC, Boca RatonGoogle Scholar
  2. 2.
    Wier B, Rothenberg CH, Grace M, Davis F (1975) Relative prognostic significance of vasospasm following subarachnoid hemorrhage. Can J Neurol Sci 2:109–114Google Scholar
  3. 3.
    Gotoh O, Mohamed AA, McCullogh J et al (1986) Nimodipine and the hemodynamic and histopathological consequences of middle cerebral artery occlusion in the rat. J Cerebr Blood Flow Metab 6:321–331CrossRefGoogle Scholar
  4. 4.
    Tettenborn D, Dycka J (1990) Prevention and treatment of delayed ischemic dysfunction in aneurysmal subarachnoid hemorrhage. Stroke 21 [Suppl IV]:85–89Google Scholar
  5. 5.
    Pickard JD, Murray GD, Illingworth L et al (1989) Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid hemorrhage. Br Med J 298:636–642CrossRefGoogle Scholar
  6. 6.
    Ohman J, Heiskanen O (1988) Effect of nimodipine on outcome of patients after aneurysmal subarachnoid hemorrhage and surgery. J Neurosurg 6:683–686Google Scholar
  7. 7.
    Zuccarello M (1989) Protective effects of 21 aminosteroid on the blood brain barrier following subarachnoid hemorrhage in the rat. Stroke 20:367–371PubMedCrossRefGoogle Scholar
  8. 8.
    Steinke DE, Wier BKA, Findlay JM et al (1989) A trial of 21 aminosteroid U74006F in a primate model of chronic cerebral vasospasm. Neurosurgery 24:179–186PubMedCrossRefGoogle Scholar
  9. 9.
    Haley Clarke E, Kassel NF, Wayne M et al (1995) Phase II trial of tirilazad in aneurysmal subarachnoid hemorrhage. J Neurosurg 82:786–790CrossRefGoogle Scholar
  10. 10.
    Kassel NF (1995) Unpublished data presented at the World Congress of Neurosurgery. Acapulco, Mexico, 1993Google Scholar
  11. 11.
    Teasdale G on behalf of the cooperative study (1992) Randomized trial of nimodipine in severe head injury: Hit 1. J Neurotrauma 9 [Suppl 2]:S545-S550PubMedGoogle Scholar
  12. 12.
    Teasdale G The European Study Group on Nimodipine in Severe Head Injury (1994) A multicenter trial of the efficacy of nimodipine on outcome after severe head injury. J Neurosurg 80:797–804CrossRefGoogle Scholar
  13. 13.
    Smith DH, Gennarelli TA, Mcintosh T (1995) The potendal of 21 aminosteroids as neuroprotective therapies in CNS injury. CNS Drugs 3(3):159–164CrossRefGoogle Scholar
  14. 14.
    Muizelar JP, Marmarou A, Young HF et al (1993) Improving the outcome of severe head injury with oxygen radical scavenger polyethylene glycol conjugate superoxide dismutase: a phase II trial. J Neurosurg 80:797–804Google Scholar
  15. 15.
    Muizelar JP (1995) Unpublished data presented at the First World Congress on Brain Injury, CopenhagenGoogle Scholar
  16. 16.
    Sanada, Nakamura T, Nishimura MC et al (1993) Effect of U74006F on neurologic functions and brain oedema after fluid percussion injury in rats. J Neurotrauma 10:65–71PubMedCrossRefGoogle Scholar
  17. 17.
    Mcintosh TK, Thomas M, Smith DH et al 0992) The novel 21 aminosteroid U74006F attenuates cerebral oedema and improves survival after brain injury in the rat. J Neurotrauma 9:33–40Google Scholar
  18. 18.
    Hall ED, Yonkers PA, McCall JM et al (1988) Effects of the 21 aminosteroid U74006F on experimental head injury in mice. J Neurosurg 68:456–461PubMedCrossRefGoogle Scholar
  19. 19.
    Bullock R, Fujisawa H (1992) The role of glutamate antagonists for treatment of CNS injury. J Neurotrauma 9 [Suppl 2]:S443-S461PubMedGoogle Scholar

Copyright information

© Springer-Verlag Italia, Milano 1996

Authors and Affiliations

  • F. Servadei
  • G. Giuliani
  • M. T. Nasi
  • A. Arista

There are no affiliations available

Personalised recommendations